GH secretagogue pharmacology
Preclinical
Primary published characterization is experimental. This is not an approved GH-deficiency or wellness therapy.
Also known as NNC 26-0161
Selective ghrelin-receptor GH secretagogue characterized mainly in experimental models. Not an approved medicine.
Ipamorelin is a pentapeptide growth hormone secretagogue that acts at the ghrelin receptor (GHSR). A 1998 paper described it as a selective GH secretagogue in experimental systems. Human therapeutic use is not established, and it is not FDA-approved.
Ipamorelin is a small synthetic peptide designed to stimulate growth hormone release via the ghrelin receptor, not via GHRH receptors.
Selectivity claims come largely from older experimental characterization, not from modern large clinical programs.
It is often marketed alongside GHRH analogs. Combination products sold online are not licensed therapies.
Ipamorelin is designed to act like a selective 'key' for the ghrelin receptor that helps the pituitary release growth hormone, at least in laboratory and animal models.
Ghrelin receptor (GHSR-1a) agonism can stimulate GH release. Older in vitro/in vivo work reported relatively less ACTH/cortisol stimulation than some earlier GH secretagogues in those models. Class effects of GH secretagogues still include GH/IGF-I elevation with attendant theoretical risks.
Step 1
Peptide
Ipamorelin
Step 2
Target
Ghrelin receptor (GHSR)
Step 3
Pathway
GH secretagogue signaling
Step 4
Observed research effect
Selective GH release in experimental characterization; human therapy not established
Primary published characterization is experimental. This is not an approved GH-deficiency or wellness therapy.
Limited human pharmacology may exist in the broader GH-secretagogue class literature; a robust, modern efficacy and safety dossier for ipamorelin as a medicine is not sufficiently established on this page.
Raun et al. (1998) characterized ipamorelin as a selective GH secretagogue in experimental models.
1998 · Animal study
Population: In vitro and animal GH-secretagogue models as reported
Objective: Characterize potency and selectivity of ipamorelin relative to other GH secretagogues.
Main finding: The paper described ipamorelin as a selective GH secretagogue in experimental models, with limited ACTH/cortisol-related activity compared with some older compounds in those models.
Limitations: Primarily preclinical. Human therapeutic use, dosing, and long-term safety are not established by this paper.
Safety information may be incomplete, especially for experimental peptides.
Safety information may be incomplete, especially for experimental peptides. Consult a qualified healthcare professional for personal medical advice.
Long-term safety: Not sufficiently established.
Evidence limitations: Selectivity in animal models does not equal clinical safety in unsupervised human use.
Administration practices vary by compound and clinical context. Follow approved prescribing information or guidance from a qualified healthcare professional. This page does not provide injection technique, mixing, or personalized dosing instructions.
Discovery
complete · 1998
Experimental characterization published.
Preclinical research
in progress
GH secretagogue models.
Human studies
in progress
Adequate modern clinical development is not established here.
Regulatory status
not started
Not an approved drug.
A ghrelin-receptor GH secretagogue characterized mainly in experimental research. It is not an approved medicine.
No.
Growth Hormone Research
Long-acting GHRH analog studied in healthy adults for prolonged GH and IGF-I secretion. Not an approved therapy for general use.
View peptide →
Growth Hormone Research
Ghrelin-receptor GH secretagogue used in some diagnostic and research contexts. Not established as an FDA-approved wellness therapy.
View peptide →
Growth Hormone Research
Older ghrelin-receptor GH secretagogue known experimentally to stimulate GH and, in some contexts, appetite. Not an approved medicine.
View peptide →
Growth Hormone Research
GHRH (1-29) analog that was previously marketed in the U.S. Current routine availability and approved status should not be assumed from historical branding.
View peptide →